Home

Bel Fuse (BELFA) Reports Q1: Everything You Need To Know Ahead Of Earnings

via StockStory

BELFA Cover Image

Electronic system and device provider Bel Fuse (NASDAQ:BELFA) will be reporting earnings tomorrow after the bell. Here’s what investors should know.

Bel Fuse beat analysts’ revenue expectations by 18.6% last quarter, reporting revenues of $149.9 million, up 7% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ EBITDA estimates.

Is Bel Fuse a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Bel Fuse’s revenue to grow 17% year on year to $149.8 million, a reversal from the 25.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.99 per share.

Bel Fuse Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bel Fuse has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Bel Fuse’s peers in the electrical equipment segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Badger Meter delivered year-on-year revenue growth of 13.2%, meeting analysts’ expectations, and Teledyne reported revenues up 7.4%, topping estimates by 1.5%. Badger Meter traded up 8.8% following the results.

Read our full analysis of Badger Meter’s results here and Teledyne’s results here.


Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

via Business Wire

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash (payable following the first commercial sale of VG-3927 if achieved within a specific period). KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-vigl/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts